Sanofi (NASDAQ:SNY) is acquiring Dynavax Technologies Corporation for $2.2 billion to expand its adult immunization portfolio with HEPLISAV-B, a two-dose hepatitis B vaccine. The deal is expected to close in Q1 2026 and has been approved by Dynavax’s board. Wall Street analysts project over 26% upside for SNY stock.

Sanofi (NASDAQ:SNY) is a global healthcare company with a focus on pharmaceuticals, vaccines, and consumer healthcare. While SNY presents investment potential, some AI stocks offer better prospects. For an undervalued AI stock poised to benefit from tariffs and onshoring trends, check out the free report on the best short-term AI stock.

Analysts have a positive outlook on Sanofi (NASDAQ:SNY), with a 12-month price target showing more than 26% upside. Steve Scala from TD Cowen reiterated a Hold rating on the stock with a $57 price target on December 17. The acquisition of Dynavax aligns with Sanofi’s strategy and is not expected to impact the company’s 2025 financial guidance.

Read more at Yahoo Finance: Sanofi (SNY) to Acquire Dynavax Technologies Corporation (DVAX)